Plain-English translation of NCT06627335 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study looks at the safety of —a newer medication for eczema—when used by pregnant women. Researchers want to compare how pregnancies and babies fare when mothers used this medication versus the more traditional steroid creams that have been used for years. This helps doctors understand whether the newer treatment is safe during pregnancy.
Pregnant women with eczema need to treat their skin condition, but doctors need to know whether this medication is safe for the developing baby. By comparing outcomes between women who used this treatment and those who used traditional steroid creams, researchers can help guide treatment decisions for pregnant patients in the future.
You likely qualify if…
You likely don't qualify if…
This is a retrospective study, meaning researchers review your existing medical and pharmacy records—you don't attend visits or take new actions. Researchers will look back at your pregnancy records, the skin treatments you used, and your infant's health outcomes during the first year of life. Participation is entirely passive; your information is extracted from insurance claims and medical databases you've already used.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States
Sponsor
Incyte Corporation
Enrollment target
~5,621 participants
Started
March 2023
Primary completion
August 2027
Age range
14 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Incyte Corporation Call Center (US)
Incyte Corporation
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.